Mylan gets DCGI nod for anti-tuberculosis drug Pretomanid for conditional access

The Drug Controller General of India (DCGI) has approved Pretomanid
for conditional access under the National Tuberculosis Elimination
Program (NTEP), Mylan said in a statement. Through the conditional
access approval from DCGI, Mylan will initially make its Pretomanid
available in India through a donation of 400 treatment courses to the
NTEP, it added.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/mylan-gets-dcgi-nod-for-anti-tuberculosis-drug-pretomanid-for-conditional-access/articleshow/77106553.cms